VivoSim Labs Inc Dossier - Source-backed chat

VivoSim Labs Inc

VIVSNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.34

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.21Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $2.8M

Shares Outstanding 13.4M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

VivoSim Labs, Inc. (formerly Organovo Holdings, Inc.) has transitioned its business model to focus on its proprietary 3D bioprinted human tissue platform (NAMkind™ liver and intestine models) for preclinical toxicology and drug testing. Following the strategic sale of its clinical-stage FXR program to Eli Lilly in March 2025 for $10 million upfront, the company operates as a lean, micro-cap biotechnology services provider. While the regulatory environment is increasingly favorable due to the FDA's shift toward non-animal New Approach Methodologies (NAMs), VivoSim remains constrained by extremely low commercial revenues ($144k in FY2025) and persistent net losses, triggering ongoing going concern warnings. Investors should maintain a Hold stance until the company demonstrates commercial traction or secures non-dilutive funding.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Commercial adoption of the NAMkind platform fails to materialize, and the company's cash runway is exhausted. Highly dilutive equity offerings or warrant-heavy raises depress the share price, or the company fails to maintain Nasdaq listing compliance.

Base CaseCentral scenario

The company slowly expands its contract research services and toxicology screening partnerships, leveraging the validation of its NAMkind models for predicting antibody-drug conjugate (ADC) toxicity. Revenue grows modestly, but the company remains dependent on equity raises or milestone payments from the Eli Lilly FXR transaction to fund operations.

Scenarios reflect our research view at the research date.

Key Investment Merits

Proprietary NovoGen bioprinting technology and validated NAMkind™ liver and intestinal models that bypass traditional animal testing.
Favorable regulatory tailwinds as the FDA actively encourages the adoption of New Approach Methodologies (NAMs).
Potential milestone payments of up to $50 million from the sale of the FXR program to Eli Lilly.

Key Investment Risks

Substantial doubt regarding the company's ability to continue as a going concern due to limited cash reserves and high burn rate.
Extremely low historical revenues ($144k in FY2025) indicating early-stage commercial adoption.
Risk of severe shareholder dilution from aggressive, warrant-heavy capital raises.

Thesis Invalidation Triggers

Failure to secure additional financing or strategic partnerships within the next 12 months.
Delisting from the Nasdaq Capital Market due to failure to meet minimum stockholder equity or bid price requirements.
Inability to achieve meaningful commercial revenue growth from the NAMkind platform.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.